Liraglutide

Generic name
Liraglutide
Brand name
ATC Code
A10BJ02
Compare …

Liraglutide

Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

No information is present at this moment.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Type 2 diabetes mellitus
  • Subcutaneous
    • 10 years up to 18 years
      • Initial dose: 0.6 mg/day in 1 dose
      • Maintenance dose: Increase dose after a minumun of 1 week to 1.2 mg/day in 1 dose. Max: 1.8 mg/day.

      • Some patients may benefit from a second dose increase to 1.8 mg/day after at least one week. 
Obesity/Overweight
  • Subcutaneous
    • ≥ 12 years
      [2]
      • Initial dose: 0.6 mg/day in 1 dose
      • Maintenance dose: increase starting dose based on tolerance in increments of 0.6 mg with an interval of at least 1 week to max. 3 mg/day in 1 dose
    • 6 years up to 18 years
      • Initial dose: 0.6 mg/day in 1 dose
      • Maintenance dose: increase starting dose based on tolerance in increments of 0.6 mg with an interval of at least 1 week to max. 3 mg/day in 1 dose

Renal impaiment in children > 3 months

GFR ≥10 ml/min/1.73m2: Dose adjustment not required.

GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects in children

In general, the frequency, type, and severity of adverse events in adolescents and in children 10 years of age and older was similar to what was observed in adult patients. Vomiting occured twice as often in adolescents as compared to adults.

The number of confirmed hypoglycemic episodes in children was higher with liraglutide (0.58 events/patient year) compared with placebo (0.29 events/patient year). In children treated with insulin prior to a confirmed hypoglycemic episode, the number was higher with liraglutide (1.82 events/patient year) compared with placebo (0.91 events/patient year). No severe hypoglycemic episodes occurred in the liraglutide-treated group.

 

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions

No information available on specific warnings and precautions in children.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Biguanides
A10BA02
Sulfonylureas
A10BB01
Combinations of oral blood glucose lowering drugs
A10BD20
Glucagon-like peptide-1 (GLP-1) analogues
A10BJ05
A10BJ01
Sodium-glucose co-transporter 2 (SGLT2) inhibitors
A10BK01
A10BK03

References

  1. Novo Nordisk A/S, SmPC Victoza (EU/1/09/529) Rev 21, 11-02-2021, www.geneesmiddeleninformatiebank.nl
  2. Novo Nordisk A/S , SmPC Saxenda (EU/1/15/992/001-003) 02-06-2021, www.geneesmiddeleninformatiebank.nl
  3. Novo Nordisk A/S, SmPC Saxenda (EU/1/15/992/001-003) Rev 19; 31-07-2025, www.ema.europa.eu
  4. Novo Nordisk A/S, SmPC Victoza (EU/1/09/529) Rev 25; 20-02-2025, www.ema.europa.eu

Changes

Therapeutic Drug Monitoring


Overdose